Alzheimer disease trials in Greece

In Greece 12 Also abroad 815

12 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Where
Athens, Ioannina, Maroussi, Patras, Thessaloniki
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00
No phaseTaking people
InRAD Observational Study
Where
Athens, Thessaloniki
Age
18 years and over
People
50,000 worldwide
Run by
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
See details and how to joinNCT07213700
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Athens, Chaïdári, Heraklion, Kifissia, Thessaloniki
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Where
Alexandroupoli, Athens, Larissa, Thessaloniki
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Heraklion
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Where
Athens, Heraklion, Marousi
Age
55 years to 90 years
People
500 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06126224 · EU 2023-504416-16-00
Phase 3Taking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Athens, Ioannina, Maroussi, Patras, Thessaloniki
Age
55 years to 90 years
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Where
Athens, Maroussi, Patras, Thessaloniki
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00
No phaseTaking people
The Effect of Combination of Mediterranean Diet and Oleocanthal in Patients With Mild Cognitive Impairment
Where
Thessaloniki
Age
60 years to 85 years
People
200
Run by
Aristotle University Of Thessaloniki
See details and how to joinNCT06705738
No phaseEnrolling by invitation
Digitally-enhanced, Decentralized, Multi-omics Observational Cohort
Where
Corfu, Thessaloniki
Age
45 years and over
People
100,000 worldwide
Run by
Greece 2021 Committee
See details and how to joinNCT04701177
No phaseTaking people
Impact of a Multicomponent Exercise Program on Cognitive and Functional Outcomes in Patients With Mild Cognitive Impairment
Where
Pátrai
Age
50 years and over
People
45
Run by
University of Patras
See details and how to joinNCT07334392
No phaseTaking people
Positive Psychology for Early Cognitive Decline: Effects on Cognitive and Brain Function
Where
Thessaloniki
People
128
Run by
Aristotle University Of Thessaloniki
See details and how to joinNCT07289061